SureTrader
Nadex Advertisement
Interactive Brokers Advertisement
Home > Boards > US Listed > Biotechs >

Cel-Sci (CVM)

CVM RSS Feed
Add CVM Price Alert      Hide Sticky   Hide Intro
Moderator: mick, Foxwoods Man, drkazmd65
Search This Board: 
Last Post: 7/23/2017 2:49:40 PM - Followers: 194 - Board type: Free - Posts Today: 2

 Cel-Sci Corporation (CVM)

http://www.cel-sci.com/

https://www.youtube.com/watch?v=auAihG3rtC4

Products In Development

Multikine® (Leukocyte Interleukin, Injection) is the full name of this investigational therapy, which, for simplicity, is referred to in the remainder of this page as Multikine*.

CANCER - MULTIKINE

Multikine, CEL-SCI's lead investigational immunotherapy, is an immunotherapeutic agent that is being developed as a potential first-line treatment for advanced primary head and neck cancer. If it were to be approved for use following completion of CEL-SCI's clinical development program, Multikine would be a different kind of therapy in the fight against cancer; one that appears to have the potential to work with the body's natural immune system in the fight against tumors.

Multikine may also have the potential to be a first in a new class of cancer immunotherapy drugs. It is the first investigational combination immunotherapy thought to have both passive and active immune properties.  More...

INFECTIOUS DISEASES - L.E.A.P.S.(TM)**

L.E.A.P.S is a patented, T-cell modulation, peptide epitope delivery technology that enables CEL-SCI to design and synthesize proprietary peptide immunogens. L.E.A.P.S. compounds consist of a small T-cell binding peptide ligand linked with a disease-associated peptide antigen.

This new technology has been shown the potential in several animal models to preferentially direct immune response to a cellular (e.g., T-cell), humoral (antibody) or mixed pathway. Diseases for which antigenic epitope sequences have been identified, such as some infectious diseases, cancer, autoimmune diseases, allergic asthma and allergy, and select CNS diseases (e.g., Alzheimer's) may be potential candidates for development using this technology platform.  More...

 

* Multikine is the trademark that CEL-SCI has registered for this investigational therapy, and this proprietary name is subject to FDA review in connection with our future anticipated regulatory submission for approval. Multikine has not been licensed or approved for sale, barter or exchange by the FDA or by any other regulatory agency. Similarly, its safety of efficacy has not been established for any use. Moreover, no definitive conclusions can be drawn from the early-phase, clinical-trials data summarized on this page or elsewhere on this website involving the investigational therapy Multikine (Leukocyte Interleukin, Injection). Further research is required, and early-phase clinical trial results must be confirmed in the well-controlled, Phase III clinical trial of this investigational therapy that is currently in progress.

** L.E.A.P.S. is the trademark of CEL-SCI for this investigational platform technology, and this proprietary name is subject to FDA review. No L.E.A.P.S. product has been approved for sale, barter or exchange by the FDA or any other regulatory agency for any use to treat disease in animals or humans. The safety or efficacy of these products has not been established for any use. Lastly, no definitive conclusions can be drawn from these early-phase, preclinical-trials data involving these investigational products

Partnering Philosophy & Corporate Partners

CEL-SCI's partnering philosophy is guided by the belief that any partnership entered into should serve the best interests of: 

  1. The patients who are/will be treated,
    The scientific, clinical, and commercial development of the medicine and
    CEL-SCI's shareholders.

CEL-SCI is open to any reasonable partnership proposals that will accelerate its being able to bring its medicines to market.

Multikine® (Leukocyte Interleukin, Injection):

Multikine (Leukocyte Interleukin, Injection) is the full name of this investigational therapy, which, for simplicity, is referred to in the remainder of this page as Multikine*.

CEL-SCI has a unique expertise in the development and manufacture of complex biologics. CEL-SCI is not a company that markets and sells drug products at the current time. Regardless, CEL-SCI believes it will be capable of marketing and selling Multikine on its own for head and neck cancer in both the United States and Europe if and once it is approved by the FDA (or EU regulators). Since its primary target is head & neck cancer surgeons, a rather small audience, CEL-SCI does not believe that a large sales force will be needed to commercialize Multikine, if and once it is approved by the FDA (or EU regulators) following the review of the total Multikine Biologics License Application.

Current Corporate Partners:

  1. Byron Biopharma
     
      a. Agreement Signed March 2009  
      b. Territory - Republic of South Africa  
      c. Revenue Share  

    Teva Pharmaceuticals Industries Ltd.
     
      a. Agreement Signed August 2008  
      b. Territory - Israel, Turkey, expanded to also cover Serbia and Croatia in August 2011.  
      c. Revenue Share  
      d. Website - http://www.tevapharm.com/  

     
    Orient Europharma Co. Ltd.
     
      a. Agreement Signed November 2000  
      b. Territory - Taiwan, Singapore, Hong Kong, Malaysia, expanded to also cover South Korea, the Philippines, Australia and New Zealand in the Fall of 2008.  
      c. Revenue Share  
      d. Website - http://www.oep.com.tw/  

     
    IDC-GP Pharm LLC 
     
      a. Agreement signed August 2011  
      b. Territory - Argentina and Venezuela  
      c. Revenue Share  
      d. Website - http://www.gp-pharm.com/  

     

Other Partnering Possibilities:

Based on the Company's L.E.A.P.S.TM** technology, as long as a disease epitope is available, CEL-SCI may be able to develop an effective treatment/vaccine using the L.E.A.P.S. technology.  The two leading candidates derived from this technology are the H1N1 treatment being developed as a possible treatment option for hospitalized patients and the Rheumatoid Arthritis treatment vaccine currently being tested in animal models of the disease.

 

* Multikine is the trademark that CEL-SCI has registered for this investigational therapy, and this proprietary name is subject to FDA review in connection with our future anticipated regulatory submission for approval. Multikine has not been licensed or approved for sale, barter or exchange by the FDA or any other regulatory agency. Similarly, its safety or efficacy has not been established for any use. Moreover, no definitive conclusions can be drawn from the early-phase, clinical-trials data summarized on this page or elsewhere on this website involving the investigational therapy Multikine (Leukocyte Interleukin, Injection). Further research is required, and early-phase clinical trial results must be confirmed in the well-controlled, Phase III clinical trial of this investigational therapy that is currently in progress.

** L.E.A.P.S. is the trademark of CEL-SCI for this investigational platform technology, and this proprietary name is subject to FDA review. No L.E.A.P.S. product has been approved for sale, barter or exchange by the FDA or any other regulatory agency for any use to treat disease in animals or humans. The safety or efficacy of these products has not been established for any use. Lastly, no definitive conclusions can be drawn from these early-phase, preclinical-trials data involving these investigational products.




http://stockcharts.com/freecharts/gallery.html?CVM

http://finance.yahoo.com/q?s=cvm&ql=1

http://stockcharts.com/h-sc/ui?s=CVM&p=D&yr=3&mn=0&dy=0&id=p60195179833

 

CVM
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
CVM News: Securities Registration Statement (s-1) 07/20/2017 03:54:15 PM
CVM News: Small Company Offering and Sale of Securities Without Registration (d) 07/17/2017 02:30:44 PM
CVM News: Prospectus Filed Pursuant to Rule 424(b)(3) (424b3) 07/06/2017 04:35:37 PM
CVM News: Current Report Filing (8-k) 07/06/2017 04:31:42 PM
CVM News: CEL-SCI Extends the Expiration Date of Series DD Warrants Issued in December 2016 07/06/2017 07:30:00 AM
PostSubject
#8718  Sticky Note Do with this information what you will,... I drkazmd65 09/26/16 01:49:06 PM
#7838  Sticky Note $CVM recent news/filings mick 01/18/16 02:09:58 PM
#5747  Sticky Note They keep coming!! Foxwoods Man 04/02/14 08:51:19 AM
#11665   Well it is not appropriate for brain tumors Foxwoods Man 07/23/17 02:49:40 PM
#11664   I see no reason Multkine can't be used Turney 07/23/17 01:04:07 PM
#11663   CVM buy 2.29 stocktrademan 07/22/17 01:06:49 PM
#11662   Is this like using a "BOOKIE"??? Turney 07/22/17 07:02:42 AM
#11661   If you had a better understanding of share learning curve 07/21/17 11:15:19 PM
#11660   Sea Alice, I've never said they weren't going warfaretrader 07/21/17 09:41:40 PM
#11659   Warfaretrader If you would like to put some cake down sea alice 07/21/17 03:59:00 PM
#11658   Sucks feel ya akamaii 07/21/17 03:06:14 PM
#11657   Does anyone here wants my 5,600 shares which ducruacuteo11 07/21/17 01:34:35 PM
#11656   Not sure why everyone here thinks that there warfaretrader 07/21/17 01:20:53 PM
#11655   They will only get money if the share Foxwoods Man 07/21/17 12:36:33 PM
#11654   I thought the FDA approved drugs like this rbl100 07/21/17 12:19:35 PM
#11653   Because they are a no revenue company and trickledownfacists 07/21/17 12:16:38 PM
#11652   why? rbl100 07/21/17 12:13:14 PM
#11651   shareholders to sell nearly 1.8 million shares at sinity 07/21/17 12:04:06 PM
#11650   An exceptional man. It is gold to not KatCat 07/20/17 10:38:56 PM
#11649   Wrong kind of cancer man,... Sucks - because even drkazmd65 07/20/17 09:21:39 PM
#11648   I hope McCain get Muiltkine Turney 07/20/17 06:48:52 PM
#11647   Latest filing if I'm reading it right: a trickledownfacists 07/20/17 06:08:48 PM
#11646   Looks like some in the board and Geert trickledownfacists 07/17/17 03:27:37 PM
#11642   I'm looking for a breakout of $2.50 level warfaretrader 07/16/17 09:48:29 PM
#11641   That may be what were missing here. warfaretrader 07/15/17 05:10:35 PM
#11640   Apologies if I missed it earlier, but... lightrock 07/14/17 10:12:05 PM
#11639   I read it, and yes I see what warfaretrader 07/14/17 06:53:37 PM
#11638   Read the Motions filed by the insurer and inventiv. sea alice 07/14/17 03:43:31 PM
#11637   I'm going to have to respectively disagree with warfaretrader 07/14/17 02:02:15 PM
#11636   CVM winning arbitration is no longer sea alice 07/14/17 07:58:55 AM
#11635   Moving up today gents akamaii 07/14/17 05:23:16 AM
#11634   Assuming cvm wins. I agree. learning curve 07/13/17 11:45:45 PM
#11633   KIT KAT sea alice 07/13/17 06:15:18 PM
#11632   Kit Kat sea alice 07/13/17 06:06:59 PM
#11631   Pride....? Ego....? trickledownfacists 07/13/17 04:32:27 PM
#11630   rwa3848 - Any idea why they didn't settle? Trustbaby 07/13/17 04:13:02 PM
#11629   I think you may be correct here. drkazmd65 07/12/17 11:11:39 PM
#11628   InVentiv, as a corporate entity after the merger, rwa3848 07/12/17 10:21:32 PM
#11627   I think inVentiv is screwed..... trickledownfacists 07/12/17 09:08:47 PM
#11626   Translation InVentiv: "Our Navigator's Policy guarantees legal fee payment rwa3848 07/12/17 08:39:28 PM
#11625   So inVentiv has asked the judge to delay trickledownfacists 07/12/17 05:31:40 PM
#11624   Agreed - mostly view this as a long-shot drkazmd65 07/12/17 04:11:17 PM
#11623   Time scale, among other factors. The stars have KatCat 07/12/17 04:04:50 PM
#11622   I'm a willing listener. I have seen payouts KatCat 07/12/17 04:01:13 PM
#11621   Oh? No delays? Let's see.....who's the one who KatCat 07/12/17 03:59:14 PM
#11620   Not how it'll work... trickledownfacists 07/12/17 03:17:47 PM
#11619   Kit Kat sea alice 07/12/17 03:16:39 PM
#11618   Thanks. Glad you enjoyed their service. KatCat 07/12/17 02:35:16 PM
#11617   Has anyone calculated how much Cash cel-sci will rwa3848 07/12/17 02:27:12 PM
#11616   Call JG Wentworth (855) 688-9669 rwa3848 07/12/17 02:18:39 PM
#11615   So even if CVM wins the arbitration the KatCat 07/12/17 02:14:07 PM
#11614   Gracias! drkazmd65 07/12/17 01:50:30 PM
#11613   Affirm trickledownfacists 07/12/17 01:44:02 PM
PostSubject